search
Back to results

Validation of the Sleep Assessment Algorithm in the Medical Application Nightly

Primary Purpose

Sleep Disorder, Nightmare

Status
Completed
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
Nightly App
Sponsored by
DreamJay Sp. z o. o.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Sleep Disorder focused on measuring sleep, nightmare, app

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Any healthy individual who meets all the following criteria may be included in the study:

  1. Age 18 to 40 years.
  2. Signed Informed Consent Form for participation in the study
  3. No chronic illnesses (A medical interview will be conducted during the participants first visit)
  4. Does not take any medication chronically (According to the medical interview with the participants during the first visit)

Exclusion Criteria:

A person who meets any one of the following criteria cannot be included in the study:

  1. Primary sleep disorders. (An in-depth medical interview during the first visit to be supplemented with: Holland Sleep Disorders Questionnaire which evaluates the risk of primary sleep disorders according to the International Classification of Sleep Disorders (ICSD-3), Athens insomnia scale which assesses the risk of insomnia and the STOP-BANG scale, evaluates the risk for sleep apnea; a journal will also be kept noting dreams between the first and second visit.
  2. History of cancer or active cancer.
  3. Disorders of the nervous system (e.g. epilepsy, migraine).
  4. Mental disorders (e.g. depression, bipolar disorder, schizophrenia).
  5. Active infection during the study. (Medical history, body temperature measurement and physical examination)
  6. Consuming within 12 hours preceding the sleep examination: coffee, caffeinated teas or other beverages containing caffeine, caffeine, or other stimulants.
  7. Consuming alcohol on the day of the examination.
  8. Pregnancy and lactation (based on the patient's own declaration, pregnancy test is not planned prior to the examination).
  9. Any contraindications to participate in the examination in the Investigator's opinion.

Sites / Locations

  • Institute of Psychiatry and Neurology in Warsaw

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

A: 3rd night with acoustic stimulation

B: 2nd night with acoustic stimulation

Arm Description

Arm A: PSG (3 nights) with Nightly App - acoustic stimulation during the 3rd night.

Arm B: PSG (3 nights) with Nightly App - acoustic stimulation during the 2nd night.

Outcomes

Primary Outcome Measures

The ICC for distribution of the total duration of standby periods during phases NREM and REM
The ICC for distribution of the total duration of standby periods during phases NREM and REM should not be less than 0.6 in the comparative analysis of results provided by the Nightly application and at least one of the visual recordings from polysomnography.

Secondary Outcome Measures

The ICC value when evaluating the accuracy of recognizing sleep phases and vigilance using the Nightly application
The ICC value when evaluating the accuracy of recognizing sleep phases and vigilance using the Nightly application and the reference method should be no less than the ICC when comparing actigraphy and the reference method
The incidence of arousal and wakening's
The stimulation produced by the Nightly application should not significantly affect the incidence of arousal and wakening's (when compared to analogous conditions without stimulation) with presumed statistical significance (p = 0.05). In other words, the aim of the experiment is to provide evidence that the distribution of arousals and wakening's measured in the study without stimulation is not statistically different from the distribution of the number of events during the Nightly application stimulation session
Evaluate the effect of acoustic stimulation - total sleep time
Total sleep time will be measured.
Evaluate the effect of acoustic stimulation - wake after sleep onset
Wake after sleep onset will be measured.
Evaluate the effect of acoustic stimulation - sleep latency
Sleep latency will be measured.

Full Information

First Posted
October 16, 2017
Last Updated
May 9, 2018
Sponsor
DreamJay Sp. z o. o.
search

1. Study Identification

Unique Protocol Identification Number
NCT03532269
Brief Title
Validation of the Sleep Assessment Algorithm in the Medical Application Nightly
Official Title
Validation of the Sleep Assessment Algorithm in the Medical Application Nightly and Comparing it to Polysomnography in 24 Healthy Individuals
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
September 1, 2017 (Actual)
Primary Completion Date
December 14, 2017 (Actual)
Study Completion Date
January 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
DreamJay Sp. z o. o.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Nightly medical application prototype is a potential, non-invasive class I medical device. The application has the potential to combine both diagnostic and therapeutic procedures for sleep. At home, Nightly measures the user's motion during sleep and then records the sleep pattern from the received data. The obtained data are then used for the diagnosis of sleep disorders (REM and NREM sleep). Using acoustic and visual stimulation, the application has the capability to support the natural process of falling asleep, provide a better night's sleep by minimizing sleep deprivation and nightmares, while awakening the user at the appropriate moment (during light sleep).
Detailed Description
The study is a cohort, single-center, randomized trial. The duration of one participant included in the study is three successive nights. Visual analysis of polysomnographic recordings taken from the second and third nights will be performed independently by two independent, blinded experts. According to the sleep architecture description derived from the Nightly application, polysomnographic and actigraphy studies will be assessed using the intraclass correlation coefficient, ICC, version "Two-Way Random". Parameters of the sleep architecture will be the average total length of the individual sleep phases (provided with standard deviations and coefficients of variability defined as the quotient of standard deviation and mean).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Disorder, Nightmare
Keywords
sleep, nightmare, app

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A: 3rd night with acoustic stimulation
Arm Type
Experimental
Arm Description
Arm A: PSG (3 nights) with Nightly App - acoustic stimulation during the 3rd night.
Arm Title
B: 2nd night with acoustic stimulation
Arm Type
Experimental
Arm Description
Arm B: PSG (3 nights) with Nightly App - acoustic stimulation during the 2nd night.
Intervention Type
Device
Intervention Name(s)
Nightly App
Intervention Description
The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.
Primary Outcome Measure Information:
Title
The ICC for distribution of the total duration of standby periods during phases NREM and REM
Description
The ICC for distribution of the total duration of standby periods during phases NREM and REM should not be less than 0.6 in the comparative analysis of results provided by the Nightly application and at least one of the visual recordings from polysomnography.
Time Frame
Through study completion - after 3rd night of PSG
Secondary Outcome Measure Information:
Title
The ICC value when evaluating the accuracy of recognizing sleep phases and vigilance using the Nightly application
Description
The ICC value when evaluating the accuracy of recognizing sleep phases and vigilance using the Nightly application and the reference method should be no less than the ICC when comparing actigraphy and the reference method
Time Frame
Through study completion - after 3rd night of PSG
Title
The incidence of arousal and wakening's
Description
The stimulation produced by the Nightly application should not significantly affect the incidence of arousal and wakening's (when compared to analogous conditions without stimulation) with presumed statistical significance (p = 0.05). In other words, the aim of the experiment is to provide evidence that the distribution of arousals and wakening's measured in the study without stimulation is not statistically different from the distribution of the number of events during the Nightly application stimulation session
Time Frame
Through study completion - after 3rd night of PSG
Title
Evaluate the effect of acoustic stimulation - total sleep time
Description
Total sleep time will be measured.
Time Frame
Through study completion - after 3rd night of PSG
Title
Evaluate the effect of acoustic stimulation - wake after sleep onset
Description
Wake after sleep onset will be measured.
Time Frame
Through study completion - after 3rd night of PSG
Title
Evaluate the effect of acoustic stimulation - sleep latency
Description
Sleep latency will be measured.
Time Frame
Through study completion - after 3rd night of PSG

10. Eligibility

Sex
All
Gender Based
Yes
Gender Eligibility Description
15 M, 15 F
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Any healthy individual who meets all the following criteria may be included in the study: Age 18 to 40 years. Signed Informed Consent Form for participation in the study No chronic illnesses (A medical interview will be conducted during the participants first visit) Does not take any medication chronically (According to the medical interview with the participants during the first visit) Exclusion Criteria: A person who meets any one of the following criteria cannot be included in the study: Primary sleep disorders. (An in-depth medical interview during the first visit to be supplemented with: Holland Sleep Disorders Questionnaire which evaluates the risk of primary sleep disorders according to the International Classification of Sleep Disorders (ICSD-3), Athens insomnia scale which assesses the risk of insomnia and the STOP-BANG scale, evaluates the risk for sleep apnea; a journal will also be kept noting dreams between the first and second visit. History of cancer or active cancer. Disorders of the nervous system (e.g. epilepsy, migraine). Mental disorders (e.g. depression, bipolar disorder, schizophrenia). Active infection during the study. (Medical history, body temperature measurement and physical examination) Consuming within 12 hours preceding the sleep examination: coffee, caffeinated teas or other beverages containing caffeine, caffeine, or other stimulants. Consuming alcohol on the day of the examination. Pregnancy and lactation (based on the patient's own declaration, pregnancy test is not planned prior to the examination). Any contraindications to participate in the examination in the Investigator's opinion.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wojciech Jernajczyk, PhD
Organizational Affiliation
Institute of Neurology and Psychiatry
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute of Psychiatry and Neurology in Warsaw
City
Warsaw
ZIP/Postal Code
02-957
Country
Poland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Validation of the Sleep Assessment Algorithm in the Medical Application Nightly

We'll reach out to this number within 24 hrs